iSpecimen Inc.
iSpecimen Inc. is listed today as iSpecimen Inc.: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2026 | $3 M | Private placement after listing | $2 to $10 million | equity, options | SEC | |
| Dec 2025 | $6 M | Private placement after listing | $2 to $10 million | equity | SEC | |
| Aug 2025 | $2 M | Private placement after listing | Under $2 million | equity, options | SEC | |
| Dec 2021 | $21 M | No. 3 | $10 to $50 million | equity, options | SEC | |
| Aug 2014 | $9 M | No. 2 | $2 to $10 million | equity | SEC | |
| Aug 2012 | $2 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company iSpecimen Inc., its revenue in fiscal 2025 came from these product and service lines: Shipping and other $190,000 (10%).
Annual report (SEC XBRL) · Dec 2025
iSpecimen Inc. chose not to state its revenue in its newest notice of a funding round (May 2026).
SEC Form D · May 2026
The industry group it chose in its notices: Other Health Care.
SEC Form D · May 2026
Products and services#
No products or services of iSpecimen Inc. are on record.
Investors#
4 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Andrew L. Ross | Person | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| Christopher Ianelli | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2021) | SEC Form 3 |
| Jill Mullan | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2021) | SEC Form 3 |
| OBF Investments, LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 13 investors.
Largest shareholders today
Institutions holding iSpecimen Inc. shares, as of Sep 30, 2026.
- Citadel Advisors LLC$0 M1.48%
- StoneX Group Inc.$0 M0.64%
- UBS Group AG$0 M0.55%
- Geode Capital Management, LLC$0 M0.49%
- Tower Research Capital LLC (TRC)$0 M0.07%
- BlackRock, Inc.$0 M0.00%
- Caitong International Asset Management Co., Ltd$0 M0.00%
- Barclays PLC$0 M0.00%
- SBI Securities Co., Ltd.$0 M0.00%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Katharyn Field | Chief Executive Officer | May 2026 |
| Katharyn Bradley Field | President | Aug 2025 |
| Robert Bradley Lim | Executive officer | Aug 2025 |
| Benjamin J. Bielak | Executive officer | Dec 2021 |
| Christopher J. Ianelli | Executive officer | Dec 2021 |
| Jill J. Mullan | Executive officer | Dec 2021 |
| Tracy J. Curley | Executive officer | Dec 2021 |
| Bruce Cranna | Executive officer | Sep 2014 |
| Christopher Ianelli | Executive officer | Sep 2014 |
| Jill Mullan | Executive officer | Sep 2014 |
| Christopher John Ianelli | Executive officer | Sep 2012 |
| Anthony Lau | Director | May 2026 |
| Arphing (Tommy) Lee | Director | May 2026 |
| Avtar Dhaliwal | Director | May 2026 |
| Siyun Yang | Director | Jan 2026 |
| Anthony Bradley Lau | Director | Aug 2025 |
| Avtar Bradley Dhaliwal | Director | Aug 2025 |
| Siyun Bradley Yang | Director | Aug 2025 |
| Andrew J. Ross | Director | Dec 2021 |
| Christopher J. Ianelli | Director | Dec 2021 |
| George J. Scholl | Director | Dec 2021 |
| Jill J. Mullan | Director | Dec 2021 |
| John L. Brooks III | Director | Dec 2021 |
| Margaret H. Lawrence | Director | Dec 2021 |
| Steven J. Gullans | Director | Dec 2021 |
| Andrew Ross | Director | Sep 2014 |
| Christopher Ianelli | Director | Sep 2014 |
| George Scholl | Director | Sep 2014 |
| Jill Mullan | Director | Sep 2014 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.